MicroRNA Regulation of the Autotaxin-Lysophosphatidic Acid Signaling Axis
Abstract
:1. Introduction to MiRNAs
2. Overview of Lysophosphatidic Acid Signaling and Autotaxin in Cancer
2.1. Lysophosphatidic Acid Signaling in Cancer
2.2. Autotaxin in Cancers
3. MiRNA as a Puppet Master of Lysophosphatidic Acid Signaling Events
3.1. Lysophosphatidic Acid Signaling Regulation
3.1.1. MiR-30c-2-3p
3.1.2. MiR-21
3.1.3. MiR-146a
3.2. Lysophosphatidic Acid Receptors
3.2.1. MiR-122
3.2.2. MiR-15b
3.2.3. MiR-200c
3.2.4. miR-23a
3.3. Autotaxin
3.3.1. MiR-29a/b/c
3.3.2. MiR-489-3p
3.3.3. MiR-101-3p
4. MiRNAs as Therapeutics
5. Conclusions
Funding
Acknowledgments
Conflicts of Interest
References
- He, L.; Hannon, G.J. MicroRNAs: Small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5, 522–531. [Google Scholar] [CrossRef]
- Esquela-Kerscher, A.; Slack, F.J. Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259–269. [Google Scholar] [CrossRef] [PubMed]
- Hashimoto, Y.; Akiyama, Y.; Yuasa, Y. Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer. PLoS ONE 2013, 8, e62589. [Google Scholar] [CrossRef] [PubMed]
- Jansson, M.D.; Lund, A.H. MicroRNA and cancer. Mol. Oncol. 2012, 6, 590–610. [Google Scholar] [CrossRef] [PubMed]
- Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843–854. [Google Scholar] [CrossRef]
- Sevignani, C.; Calin, G.A.; Siracusa, L.D.; Croce, C.M. Mammalian microRNAs: A small world for fine-tuning gene expression. Mamm. Genome 2006, 17, 189–202. [Google Scholar] [CrossRef]
- Chen, P.Y.; Weinmann, L.; Gaidatzis, D.; Pei, Y.; Zavolan, M.; Tuschl, T.; Meister, G. Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008, 14, 263–274. [Google Scholar] [CrossRef]
- Chalfie, M.; Horvitz, H.R.; Sulston, J.E. Mutations that lead to reiterations in the cell lineages of C. elegans. Cell 1981, 24, 59–69. [Google Scholar] [CrossRef]
- Reinhart, B.J.; Slack, F.J.; Basson, M.; Pasquinelli, A.E.; Bettinger, J.C.; Rougvie, A.E.; Horvitz, H.R.; Ruvkun, G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403, 901–906. [Google Scholar] [CrossRef]
- Mills, G.B.; Moolenaar, W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 2003, 3, 582–591. [Google Scholar] [CrossRef]
- Westermann, A.M.; Havik, E.; Postma, F.R.; Beijnen, J.H.; Dalesio, O.; Moolenaar, W.H.; Rodenhuis, S. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann. Oncol. 1998, 9, 437–442. [Google Scholar] [CrossRef]
- Eichholtz, T.; Jalink, K.; Fahrenfort, I.; Moolenaar, W.H. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 1993, 291, 677–680. [Google Scholar] [CrossRef] [Green Version]
- Xu, Y.; Gaudette, D.C.; Boynton, J.D.; Frankel, A.; Fang, X.J.; Sharma, A.; Hurteau, J.; Casey, G.; Goodbody, A.; Mellors, A.; et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res. 1995, 1, 1223–1232. [Google Scholar]
- Frankel, A.; Mills, G.B. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin. Cancer Res. 1996, 2, 1307–1313. [Google Scholar]
- Xu, Y.; Shen, Z.; Wiper, D.W.; Wu, M.; Morton, R.E.; Elson, P.; Kennedy, A.W.; Belinson, J.; Markman, M.; Casey, G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. Jama 1998, 280, 719–723. [Google Scholar] [CrossRef]
- Murph, M.M.; Liu, W.; Yu, S.; Lu, Y.; Hall, H.; Hennessy, B.T.; Lahad, J.; Schaner, M.; Helland, A.; Kristensen, G.; et al. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS ONE 2009, 4, e5583. [Google Scholar] [CrossRef]
- Hecht, J.H.; Weiner, J.A.; Post, S.R.; Chun, J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 1996, 135, 1071–1083. [Google Scholar] [CrossRef]
- Bandoh, K.; Aoki, J.; Hosono, H.; Kobayashi, S.; Kobayashi, T.; Murakami-Murofushi, K.; Tsujimoto, M.; Arai, H.; Inoue, K. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 1999, 274, 27776–27785. [Google Scholar] [CrossRef]
- Noguchi, K.; Ishii, S.; Shimizu, T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 2003, 278, 25600–25606. [Google Scholar] [CrossRef]
- Lee, C.W.; Rivera, R.; Gardell, S.; Dubin, A.E.; Chun, J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 2006, 281, 23589–23597. [Google Scholar] [CrossRef]
- Kotarsky, K.; Boketoft, A.; Bristulf, J.; Nilsson, N.E.; Norberg, A.; Hansson, S.; Owman, C.; Sillard, R.; Leeb-Lundberg, L.M.; Olde, B. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther. 2006, 318, 619–628. [Google Scholar] [CrossRef]
- Pasternack, S.M.; von Kugelgen, I.; Aboud, K.A.; Lee, Y.A.; Ruschendorf, F.; Voss, K.; Hillmer, A.M.; Molderings, G.J.; Franz, T.; Ramirez, A.; et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat. Genet. 2008, 40, 329–334. [Google Scholar] [CrossRef]
- Tabata, K.; Baba, K.; Shiraishi, A.; Ito, M.; Fujita, N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 2007, 363, 861–866. [Google Scholar] [CrossRef]
- McIntyre, T.M.; Pontsler, A.V.; Silva, A.R.; St Hilaire, A.; Xu, Y.; Hinshaw, J.C.; Zimmerman, G.A.; Hama, K.; Aoki, J.; Arai, H.; et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. USA 2003, 100, 131–136. [Google Scholar] [CrossRef]
- Murakami, M.; Shiraishi, A.; Tabata, K.; Fujita, N. Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 2008, 371, 707–712. [Google Scholar] [CrossRef]
- Rai, V.; Toure, F.; Chitayat, S.; Pei, R.; Song, F.; Li, Q.; Zhang, J.; Rosario, R.; Ramasamy, R.; Chazin, W.J.; et al. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J. Exp. Med. 2012, 209, 2339–2350. [Google Scholar] [CrossRef] [Green Version]
- Lee, B.H.; Kim, J.; Lee, R.M.; Choi, S.H.; Kim, H.J.; Hwang, S.H.; Lee, M.K.; Bae, C.S.; Kim, H.C.; Rhim, H.; et al. Gintonin enhances performance of mice in rotarod test: Involvement of lysophosphatidic acid receptors and catecholamine release. Neurosci. Lett. 2016, 612, 256–260. [Google Scholar] [CrossRef]
- Yu, S.; Murph, M.M.; Lu, Y.; Liu, S.; Hall, H.S.; Liu, J.; Stephens, C.; Fang, X.; Mills, G.B. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl. Cancer Inst. 2008, 100, 1630–1642. [Google Scholar] [CrossRef]
- Murph, M.M.; Nguyen, G.H.; Radhakrishna, H.; Mills, G.B. Sharpening the edges of understanding the structure/function of the LPA1 receptor: Expression in cancer and mechanisms of regulation. Biochim. Biophys. Acta 2008, 1781, 547–557. [Google Scholar] [CrossRef] [Green Version]
- Hennessy, B.T.; Murph, M.; Nanjundan, M.; Carey, M.; Auersperg, N.; Almeida, J.; Coombes, K.R.; Liu, J.; Lu, Y.; Gray, J.W.; et al. Ovarian cancer: Linking genomics to new target discovery and molecular markers--the way ahead. Adv. Exp. Med. Biol. 2008, 617, 23–40. [Google Scholar]
- Liu, S.; Murph, M.; Panupinthu, N.; Mills, G.B. ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 2009, 8, 3695–3701. [Google Scholar] [CrossRef] [Green Version]
- Liu, S.; Umezu-Goto, M.; Murph, M.; Lu, Y.; Liu, W.; Zhang, F.; Yu, S.; Stephens, L.C.; Cui, X.; Murrow, G.; et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009, 15, 539–550. [Google Scholar] [CrossRef]
- Stracke, M.L.; Krutzsch, H.C.; Unsworth, E.J.; Arestad, A.; Cioce, V.; Schiffmann, E.; Liotta, L.A. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 1992, 267, 2524–2529. [Google Scholar]
- Brindley, D.N.; Benesch, M.G.K.; Murph, M.M. Melanoma—Current Clinical Management and Future Therapeutics; InTech Open: London, UK, 2015; pp. 297–324. [Google Scholar]
- Umezu-Goto, M.; Kishi, Y.; Taira, A.; Hama, K.; Dohmae, N.; Takio, K.; Yamori, T.; Mills, G.B.; Inoue, K.; Aoki, J.; et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 2002, 158, 227–233. [Google Scholar] [CrossRef]
- Nam, S.W.; Clair, T.; Kim, Y.S.; McMarlin, A.; Schiffmann, E.; Liotta, L.A.; Stracke, M.L. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 2001, 61, 6938–6944. [Google Scholar]
- Xu, A.; Khan, M.A.K.; Chen, F.; Zhong, Z.; Chen, H.C.; Song, Y. Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression. Med. Oncol. 2016, 33, e131. [Google Scholar] [CrossRef]
- Kehlen, A.; Englert, N.; Seifert, A.; Klonisch, T.; Dralle, H.; Langner, J.; Hoang-Vu, C. Expression, regulation and function of autotaxin in thyroid carcinomas. Int. J. Cancer 2004, 109, 833–838. [Google Scholar] [CrossRef]
- Kishi, Y.; Okudaira, S.; Tanaka, M.; Hama, K.; Shida, D.; Kitayama, J.; Yamori, T.; Aoki, J.; Fujimaki, T.; Arai, H. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J. Biol. Chem. 2006, 281, 17492–17500. [Google Scholar] [CrossRef]
- Kuppa, S.S.; Jia, W.; Liu, S.; Nguyen, H.; Smyth, S.S.; Mills, G.B.; Dobbin, K.K.; Hardman, W.J.; Murph, M.M. Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p. Cancer Lett. 2018, 432, 84–92. [Google Scholar] [CrossRef]
- Masuda, A.; Nakamura, K.; Izutsu, K.; Igarashi, K.; Ohkawa, R.; Jona, M.; Higashi, K.; Yokota, H.; Okudaira, S.; Kishimoto, T.; et al. Serum autotaxin measurement in haematological malignancies: A promising marker for follicular lymphoma. Br. J. Haematol. 2008, 143, 60–70. [Google Scholar] [CrossRef]
- Murph, M.M.; Jiang, G.W.; Altman, M.K.; Jia, W.; Nguyen, D.T.; Fambrough, J.M.; Hardman, W.J.; Nguyen, H.T.; Tran, S.K.; Alshamrani, A.A.; et al. Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma. Bioorg. Med. Chem. 2015, 23, 5999–6013. [Google Scholar] [CrossRef] [Green Version]
- van Meeteren, L.A.; Ruurs, P.; Stortelers, C.; Bouwman, P.; van Rooijen, M.A.; Pradere, J.P.; Pettit, T.R.; Wakelam, M.J.; Saulnier-Blache, J.S.; Mummery, C.L.; et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell Biol. 2006, 26, 5015–5022. [Google Scholar] [CrossRef]
- Tanaka, M.; Okudaira, S.; Kishi, Y.; Ohkawa, R.; Iseki, S.; Ota, M.; Noji, S.; Yatomi, Y.; Aoki, J.; Arai, H. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 2006, 281, 25822–25830. [Google Scholar] [CrossRef]
- Altman, M.K.; Gopal, V.; Jia, W.; Yu, S.; Hall, H.; Mills, G.B.; McGinnis, A.C.; Bartlett, M.G.; Jiang, G.; Madan, D.; et al. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol. Cancer 2010, 9, e140. [Google Scholar] [CrossRef]
- Jia, W.; Tran, S.K.; Ruddick, C.A.; Murph, M.M. The Src homology 3 binding domain is required for lysophosphatidic acid 3 receptor-mediated cellular viability in melanoma cells. Cancer Lett. 2015, 356, 589–596. [Google Scholar] [CrossRef]
- Baker, D.L.; Fujiwara, Y.; Pigg, K.R.; Tsukahara, R.; Kobayashi, S.; Murofushi, H.; Uchiyama, A.; Murakami-Murofushi, K.; Koh, E.; Bandle, R.W.; et al. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J. Biol. Chem. 2006, 281, 22786–22793. [Google Scholar] [CrossRef]
- Murph, M.M. Research on Melanoma: A Glimpse into Current Directions and Future Trends; BoD–Books on Demand: Norderstedt, Germany, 2011. [Google Scholar]
- Mazereeuw-Hautier, J.; Gres, S.; Fanguin, M.; Cariven, C.; Fauvel, J.; Perret, B.; Chap, H.; Salles, J.P.; Saulnier-Blache, J.S. Production of lysophosphatidic acid in blister fluid: Involvement of a lysophospholipase D activity. J. Investig. Dermatol. 2005, 125, 421–427. [Google Scholar] [CrossRef]
- Dvinge, H.; Git, A.; Graf, S.; Salmon-Divon, M.; Curtis, C.; Sottoriva, A.; Zhao, Y.; Hirst, M.; Armisen, J.; Miska, E.A.; et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013, 497, e378. [Google Scholar] [CrossRef]
- Byrnes, C.C.; Jia, W.; Alshamrani, A.A.; Kuppa, S.S.; Murph, M.M. miR-122-5p expression and secretion in melanoma cells is amplified by the LPAR3 SH3-binding domain to regulate Wnt1. Mol. Cancer Res. 2019, 17, 299–309. [Google Scholar] [CrossRef]
- Jia, W.; Eneh, J.O.; Ratnaparkhe, S.; Altman, M.K.; Murph, M.M. MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9. Mol. Cancer Res. 2011, 9, 1732–1745. [Google Scholar] [CrossRef]
- Byrd, A.E.; Aragon, I.V.; Brewer, J.W. MicroRNA-30c-2* limits expression of proadaptive factor XBP1 in the unfolded protein response. J. Cell Biol. 2012, 196, 689–698. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mathew, L.K.; Lee, S.S.; Skuli, N.; Rao, S.; Keith, B.; Nathanson, K.L.; Lal, P.; Simon, M.C. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2alpha activity. Cancer Discov. 2014, 4, 53–60. [Google Scholar] [CrossRef] [PubMed]
- Shukla, K.; Sharma, A.K.; Ward, A.; Will, R.; Hielscher, T.; Balwierz, A.; Breunig, C.; Munstermann, E.; Konig, R.; Keklikoglou, I.; et al. MicroRNA-30c-2-3p negatively regulates NF-kappaB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. Mol. Oncol. 2015, 9, 1106–1119. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Cai, M.; Jiang, D.; Xu, L. Upregulated LncRNA-CCAT1 promotes hepatocellular carcinoma progression by functioning as miR-30c-2-3p sponge. Cell Biochem. Funct. 2019, 37, 84–92. [Google Scholar] [CrossRef] [PubMed]
- Ma, H.; Chen, P.; Sang, C.; Huang, D.; Geng, Q.; Wang, L. Modulation of apoptosis-related microRNAs following myocardial infarction in fat-1 transgenic mice vs. wild-type mice. J. Cell Mol. Med. 2018, 22, 5698–5707. [Google Scholar] [CrossRef] [PubMed]
- Tang, C.T.; Liang, Q.; Yang, L.; Lin, X.L.; Wu, S.; Chen, Y.; Zhang, X.T.; Gao, Y.J.; Ge, Z.Z. RAB31 Targeted by MiR-30c-2-3p regulates the GLI1 signaling pathway, affecting gastric cancer cell proliferation and apoptosis. Front. Oncol. 2018, 8, e554. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, H.T.; Jia, W.; Beedle, A.M.; Kennedy, E.J.; Murph, M.M. Lysophosphatidic Acid Mediates Activating Transcription Factor 3 Expression Which Is a Target for Post-Transcriptional Silencing by miR-30c-2-3p. PLoS ONE 2015, 10, e0139489. [Google Scholar] [CrossRef] [PubMed]
- Kuhlmann, J.D.; Baraniskin, A.; Hahn, S.A.; Mosel, F.; Bredemeier, M.; Wimberger, P.; Kimmig, R.; Kasimir-Bauer, S. Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer. Clin. Chem. 2014, 60, 206–213. [Google Scholar] [CrossRef] [PubMed]
- Chan, J.A.; Krichevsky, A.M.; Kosik, K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65, 6029–6033. [Google Scholar] [CrossRef]
- Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133, 647–658. [Google Scholar] [CrossRef]
- Iorio, M.V.; Visone, R.; Di Leva, G.; Donati, V.; Petrocca, F.; Casalini, P.; Taccioli, C.; Volinia, S.; Liu, C.G.; Alder, H.; et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67, 8699–8707. [Google Scholar] [CrossRef] [PubMed]
- Sahay, D.; Leblanc, R.; Grunewald, T.G.; Ambatipudi, S.; Ribeiro, J.; Clezardin, P.; Peyruchaud, O. The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget 2015, 6, 20604–20620. [Google Scholar] [CrossRef] [PubMed]
- Du, J.; Sun, C.; Hu, Z.; Yang, Y.; Zhu, Y.; Zheng, D.; Gu, L.; Lu, X. Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling. PLoS ONE 2010, 5, e15940. [Google Scholar] [CrossRef] [PubMed]
- Crone, S.G.; Jacobsen, A.; Federspiel, B.; Bardram, L.; Krogh, A.; Lund, A.H.; Friis-Hansen, L. MicroRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-kappaB by targeting CARD10 and COPS8 in gastric cancer. Mol. Cancer 2012, 11, e71. [Google Scholar] [CrossRef] [PubMed]
- Hou, J.; Wang, P.; Lin, L.; Liu, X.; Ma, F.; An, H.; Wang, Z.; Cao, X. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J. Immunol. 2009, 183, 2150–2158. [Google Scholar] [CrossRef]
- Bhaumik, D.; Scott, G.K.; Schokrpur, S.; Patil, C.K.; Campisi, J.; Benz, C.C. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008, 27, 5643–5647. [Google Scholar] [CrossRef]
- Jopling, C.L.; Yi, M.; Lancaster, A.M.; Lemon, S.M.; Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309, 1577–1581. [Google Scholar] [CrossRef]
- Fong, M.Y.; Zhou, W.; Liu, L.; Alontaga, A.Y.; Chandra, M.; Ashby, J.; Chow, A.; O’Connor, S.T.; Li, S.; Chin, A.R.; et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 2015, 17, 183–194. [Google Scholar] [CrossRef] [Green Version]
- Maierthaler, M.; Benner, A.; Hoffmeister, M.; Surowy, H.; Jansen, L.; Knebel, P.; Chang-Claude, J.; Brenner, H.; Burwinkel, B. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int. J. Cancer 2017, 140, 176–187. [Google Scholar] [CrossRef]
- Ofir, M.; Hacohen, D.; Ginsberg, D. MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol. Cancer Res. 2011, 9, 440–447. [Google Scholar] [CrossRef]
- Xia, L.; Zhang, D.; Du, R.; Pan, Y.; Zhao, L.; Sun, S.; Hong, L.; Liu, J.; Fan, D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 2008, 123, 372–379. [Google Scholar] [CrossRef] [PubMed]
- MacLean, J.A., 2nd; King, M.L.; Okuda, H.; Hayashi, K. WNT7A regulation by miR-15b in ovarian cancer. PLoS ONE 2016, 11, e0156109. [Google Scholar] [CrossRef] [PubMed]
- Li, G.C.; Qin, X.L.; Song, H.H.; Li, Y.N.; Qiu, Y.Y.; Cui, S.C.; Wang, Y.S.; Wang, H.; Gong, J.L. Upregulated microRNA-15b alleviates ovarian cancer through inhitbition of the PI3K/Akt pathway by targeting LPAR3. J. Cell Physiol. 2019. [Google Scholar] [CrossRef] [PubMed]
- Adam, L.; Zhong, M.; Choi, W.; Qi, W.; Nicoloso, M.; Arora, A.; Calin, G.; Wang, H.; Siefker-Radtke, A.; McConkey, D.; et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15, 5060–5072. [Google Scholar] [CrossRef] [PubMed]
- Gregory, P.A.; Bert, A.G.; Paterson, E.L.; Barry, S.C.; Tsykin, A.; Farshid, G.; Vadas, M.A.; Khew-Goodall, Y.; Goodall, G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10, 593–601. [Google Scholar] [CrossRef]
- Burk, U.; Schubert, J.; Wellner, U.; Schmalhofer, O.; Vincan, E.; Spaderna, S.; Brabletz, T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9, 582–589. [Google Scholar] [CrossRef] [Green Version]
- Howe, E.N.; Cochrane, D.R.; Richer, J.K. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res. 2011, 13, e45. [Google Scholar] [CrossRef]
- Elson-Schwab, I.; Lorentzen, A.; Marshall, C.J. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS ONE 2010, 5, e13176. [Google Scholar] [CrossRef]
- Luna, C.; Li, G.; Huang, J.; Qiu, J.; Wu, J.; Yuan, F.; Epstein, D.L.; Gonzalez, P. Regulation of trabecular meshwork cell contraction and intraocular pressure by miR-200c. PLoS ONE 2012, 7, e51688. [Google Scholar] [CrossRef]
- Van Leeuwen, F.N.; Olivo, C.; Grivell, S.; Giepmans, B.N.; Collard, J.G.; Moolenaar, W.H. Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1. J. Biol. Chem. 2003, 278, 400–406. [Google Scholar] [CrossRef]
- Yang, J.; Nie, Y.; Wang, F.; Hou, J.; Cong, X.; Hu, S.; Chen, X. Reciprocal regulation of miR-23a and lysophosphatidic acid receptor signaling in cardiomyocyte hypertrophy. Biochim. Biophys. Acta 2013, 1831, 1386–1394. [Google Scholar] [CrossRef] [PubMed]
- Naz, S.; Kolmert, J.; Yang, M.; Reinke, S.N.; Kamleh, M.A.; Snowden, S.; Heyder, T.; Levanen, B.; Erle, D.J.; Skold, C.M.; et al. Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD. Eur. Respir. J. 2017, 49, e1602322. [Google Scholar] [CrossRef] [PubMed]
- Baker, D.L.; Desiderio, D.M.; Miller, D.D.; Tolley, B.; Tigyi, G.J. Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal. Biochem. 2001, 292, 287–295. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Lyu, L.; Zhang, X.; Zhang, J. Autotaxin is a novel target of microRNA-101-3p. FEBS Open Bio 2019, 9, 707–716. [Google Scholar] [CrossRef] [PubMed]
- Hanna, J.; Hossain, G.S.; Kocerha, J. The Potential for microRNA Therapeutics and Clinical Research. Front. Genet. 2019, 10, e478. [Google Scholar] [CrossRef] [PubMed]
- Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 2017, 16, 203–222. [Google Scholar] [CrossRef] [PubMed]
- Seto, A.G.; Beatty, X.; Lynch, J.M.; Hermreck, M.; Tetzlaff, M.; Duvic, M.; Jackson, A.L. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br. J. Haematol. 2018, 183, 428–444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Teplyuk, N.M.; Uhlmann, E.J.; Wong, A.H.; Karmali, P.; Basu, M.; Gabriely, G.; Jain, A.; Wang, Y.; Chiocca, E.A.; Stephens, R.; et al. MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma. Oncotarget 2015, 6, 3770–3783. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Teplyuk, N.M.; Uhlmann, E.J.; Gabriely, G.; Volfovsky, N.; Wang, Y.; Teng, J.; Karmali, P.; Marcusson, E.; Peter, M.; Mohan, A.; et al. Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: First steps toward the clinic. EMBO Mol. Med. 2016, 8, 268–287. [Google Scholar] [CrossRef] [PubMed]
miRNA | Target | Alteration |
---|---|---|
miR-15b | BCL-2, LPAR3, WNT7A | LPAR3 mRNA and protein |
miR-21 | PTEN | Upregulated by LPAR1 signaling through the PI3K pathway |
miR-23a | LPAR1 | Reduced LPAR1 through LPAR3 in cardiomyocyte hypertrophy |
miR-29a/b/c | ATX/ENPP2 | ATX mRNA and protein |
miR-30c-2-3p | ATF3, BCL-9, CCNE1, HIF2A, RAB31, TRADD, XBP1 | Lysophosphatidic acid signaling, cell cycle and death |
miR-101-3p | ATX/ENPP2 | ATX mRNA and protein |
miR-122-5p | WNT1 | Lysophosphatidic acid signaling through LPAR3 |
miR-146a | COPS8, CAR10 | Modest reduction of NF-kB activation and cytokine mRNA by 25 μM lysophosphatidic acid |
miR-200c | LPAR1 | Cell contraction |
miR-489-3p | MEK1 | Feedback loop with autotaxin signaling |
© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Murph, M.M. MicroRNA Regulation of the Autotaxin-Lysophosphatidic Acid Signaling Axis. Cancers 2019, 11, 1369. https://doi.org/10.3390/cancers11091369
Murph MM. MicroRNA Regulation of the Autotaxin-Lysophosphatidic Acid Signaling Axis. Cancers. 2019; 11(9):1369. https://doi.org/10.3390/cancers11091369
Chicago/Turabian StyleMurph, Mandi M. 2019. "MicroRNA Regulation of the Autotaxin-Lysophosphatidic Acid Signaling Axis" Cancers 11, no. 9: 1369. https://doi.org/10.3390/cancers11091369